Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC)
NCT02745132, Phase 4, Unknown, Instituto de Investigación Marqués de Valdecilla
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC) | ClinicalTrials.gov |
| NCT number | NCT02745132 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 80 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Instituto de Investigación Marqués de Valdecilla | ClinicalTrials.gov |
| Conditions | Hepatitis C | ClinicalTrials.gov |
| Interventions | Neuropsychological evaluation and Brain MRI | ClinicalTrials.gov |
| First posted | 2016-04-20 | ClinicalTrials.gov |
| Last updated | 2016-04-21 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes in Continuous Performance Test (CPT) score | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Cognitive impairment, particularly Attention and reaction time | ClinicalTrials.gov |
| Secondary | Changes in Digits forward and backward WAIS-III subtest scores | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Cognitive impairment, particularly Working memory | ClinicalTrials.gov |
| Secondary | Changes in Digit symbol WAIS-III subtest score | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Information processing speed | ClinicalTrials.gov |
| Secondary | Changes in Trail Making Test (TMT) Parts A & B scores | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Information processing speed | ClinicalTrials.gov |
| Secondary | Changes in Letter FAS score | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Verbal fluency | ClinicalTrials.gov |
| Secondary | Changes in animal category subtest score | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Verbal fluency | ClinicalTrials.gov |
| Secondary | Changes in Rey Auditory Verbal Learning Test (RAVLT) scores | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Learning and memory | ClinicalTrials.gov |
| Secondary | Changes in Rey Copy Figure(RCF) scores | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Learning and memory | ClinicalTrials.gov |
| Secondary | Changes in Grooved Pegboard score | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Motor functioning | ClinicalTrials.gov |
| Secondary | Changes in Tower of London score | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Executive functions | ClinicalTrials.gov |
| Secondary | Changes in Stroop color-word test scores | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Executive functions | ClinicalTrials.gov |
| Secondary | Changes in cortical thickness | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Basal Neuroimaging findings in HCV infected patients and changes after DAA treatment (Assesed through structural, diffusion and functional MRI). | ClinicalTrials.gov |
| Secondary | Changes in cortical surface área assessed by MRI | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Basal Neuroimaging findings in HCV infected patients and changes after DAA treatment (Assesed through structural, diffusion and functional MRI). | ClinicalTrials.gov |
| Secondary | Changes in cortical surface volumen assessed by MRI | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Basal Neuroimaging findings in HCV infected patients and changes after DAA treatment (Assesed through structural, diffusion and functional MRI). | ClinicalTrials.gov |
| Secondary | Sustained Viral Response | 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Data on efficacy of treatments | ClinicalTrials.gov |
| Secondary | Advers events | up to 24 weeks | Data on safety | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 4
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 7
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Continuous Performance Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Tower Planning | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)